Diversify Advisory Services LLC Cuts Holdings in Merck & Co., Inc. $MRK

Diversify Advisory Services LLC reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 38.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,884 shares of the company’s stock after selling 12,372 shares during the period. Diversify Advisory Services LLC’s holdings in Merck & Co., Inc. were worth $1,640,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. DLD Asset Management LP acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth about $2,889,340,000. Norges Bank acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $2,858,570,000. Franklin Resources Inc. lifted its stake in Merck & Co., Inc. by 23.5% during the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock valued at $2,139,901,000 after purchasing an additional 5,135,748 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Merck & Co., Inc. by 35.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after acquiring an additional 5,094,088 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 9.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after acquiring an additional 4,636,183 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the subject of a number of recent analyst reports. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price target for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Scotiabank raised their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, February 25th. They set an “outperform” rating and a $142.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $125.88.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage trial wins for oncology and HIV programs (KEYTRUDA, WELIREG regimens and DOR/ISL HIV therapy) that show improved survival and broadened indications—these readouts raise near‑term revenue potential and long‑term pipeline value. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Stock moving higher within the S&P 500 — market‑level strength and rotation into large pharma/defensive names is supporting MRK’s price action. Merck & Co. (NYSE:MRK) Moves Higher Within S&P 500 Index Amid Gains
• Positive Sentiment: Expanding neuroendocrine carcinoma market and other oncology indications — market forecasts to 2036 increase the addressable opportunity for Merck’s targeted therapies, supporting longer‑term growth assumptions for KEYTRUDA and companion assets. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
• Neutral Sentiment: Vaccine franchise market reports (Ervebo, M‑M‑R II, Pneumovax 23, Elonva) highlight steady long‑term demand and niche growth opportunities—positive background but unlikely to move near‑term results absent new approvals or major contract wins. Ervebo (Merck & Co) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
• Negative Sentiment: Persistent weakness in Gardasil sales (down ~39% in 2025 with weak China demand) — management expects no near‑term rebound, which pressures top‑line growth and investor expectations for vaccine contribution to revenue. Will Weak Gardasil Sales Continue to Weigh on MRK’s Top Line in 2026?
• Negative Sentiment: RBC caution on Winrevair — analyst says the COPD candidate must show a ≥20‑meter improvement in 6‑minute walk to restore confidence; this raises clinical/regulatory uncertainty that could limit upside for that program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $117.14 on Wednesday. The business’s 50 day moving average is $114.64 and its two-hundred day moving average is $99.14. The company has a market cap of $289.61 billion, a P/E ratio of 16.09, a P/E/G ratio of 2.27 and a beta of 0.27. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Transactions at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 5,000 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares in the company, valued at approximately $3,759,460.58. The trade was a 13.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This trade represents a 19.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is currently owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.